Literature DB >> 14663488

Monoclonal antibody therapeutics and apoptosis.

Dale L Ludwig1, Daniel S Pereira, Zhenping Zhu, Daniel J Hicklin, Peter Bohlen.   

Abstract

The potential for disease-specific targeting and low toxicity profiles have made monoclonal antibodies attractive therapeutic drug candidates. Antibody-mediated target cell killing is frequently associated with immune effector mechanisms such as antibody-directed cellular cytotoxicity, but they can also be induced by apoptotic processes. Antibody-directed mechanisms, including antigen crosslinking, activation of death receptors, and blockade of ligand-receptor growth or survival pathways, can elicit the induction of apoptosis in targeted cells. Depending on their mechanism of action, monoclonal antibodies can induce targeted cell-specific killing alone or can enhance target cell susceptibility to chemo- or radiotherapeutics by effecting the modulation of antiapoptotic pathways. This review will focus on the mechanisms by which antibodies are capable of eliciting programmed cell death either directly or indirectly within tumor cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14663488     DOI: 10.1038/sj.onc.1207104

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  Separation of SSEA-4 and TRA-1-60 labelled undifferentiated human embryonic stem cells from a heterogeneous cell population using magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS).

Authors:  Chui Yee Fong; Gary S L Peh; Kalamegam Gauthaman; Ariff Bongso
Journal:  Stem Cell Rev Rep       Date:  2009-01-31       Impact factor: 5.739

2.  A novel screening method to assess developability of antibody-like molecules.

Authors:  Neeraj Kohli; Nidhi Jain; Melissa L Geddie; Maja Razlog; Lihui Xu; Alexey A Lugovskoy
Journal:  MAbs       Date:  2015       Impact factor: 5.857

3.  Unbiased in-depth characterization of CEX fractions from a stressed monoclonal antibody by mass spectrometry.

Authors:  François Griaud; Blandine Denefeld; Manuel Lang; Héloïse Hensinger; Peter Haberl; Matthias Berg
Journal:  MAbs       Date:  2017-04-05       Impact factor: 5.857

4.  Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors.

Authors:  Feng Wang-Johanning; Kiera Rycaj; Joshua B Plummer; Ming Li; Bingnan Yin; Katherine Frerich; Jeremy G Garza; Jianjun Shen; Kevin Lin; Peisha Yan; Sharon A Glynn; Tiffany H Dorsey; Kelly K Hunt; Stefan Ambs; Gary L Johanning
Journal:  J Natl Cancer Inst       Date:  2012-01-12       Impact factor: 13.506

5.  Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis.

Authors:  S Kevin Li; Mark R Liddell; He Wen
Journal:  J Pharm Biomed Anal       Date:  2011-01-05       Impact factor: 3.935

6.  Excess reactive oxygen species production mediates monoclonal antibody-induced human embryonic stem cell death via oncosis.

Authors:  Ji Yun Zheng; Heng Liang Tan; Paul Thomas Matsudaira; Andre Choo
Journal:  Cell Death Differ       Date:  2017-01-20       Impact factor: 15.828

7.  Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells.

Authors:  Irene Guendel; Sergey Iordanskiy; Gavin C Sampey; Rachel Van Duyne; Valerie Calvert; Emanuel Petricoin; Mohammed Saifuddin; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  J Neurovirol       Date:  2015-02-12       Impact factor: 2.643

8.  Tumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric cancer.

Authors:  Hyuk-Joon Lee; Hye Seung Lee; Keun Hur; Woo Ho Kim; Kazuyoshi Yanagihara; Karl-Friedrich Becker; Kuhn Uk Lee; Han-Kwang Yang
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-19       Impact factor: 4.553

Review 9.  Monoclonal antibody mechanisms of action in cancer.

Authors:  George J Weiner
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.

Authors:  Tameka A Bailey; Haitao Luan; Robert J Clubb; Mayumi Naramura; Vimla Band; Srikumar M Raja; Hamid Band
Journal:  J Carcinog       Date:  2011-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.